Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells

Blood

Volumn 110, Issue 5, 2007, Pages 1448-1457

  Zhang, Fang ^a   Thornhill, Susannah I ^a   Howe, Steven J ^a   Ulaganathan, Meera ^a   Schambach, Axel ^b   Sinclair, Joanna ^a   Kinnon, Christine ^a   Gaspar, H Bobby ^a,c   Antoniou, Michael ^d   Thrasher, Adrian J ^a,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

A2UCOE; GENOMIC DNA; LENTIVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POPULATION; CHROMATIN; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GENE EXPRESSION; GENE SILENCING; GENE THERAPY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN FOCUS FORMING VIRUS; TRANSCRIPTION INITIATION; TRANSGENE;

EID: 34548843603     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-12-060814     Document Type: Article

References (50)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669-672.
2. Aiuti A, Slavin S, Aker M, et al. Correction of ADASCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410-2413.
3. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364:2181-2187.
4. Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther. 2006;14:505-513.
5. Schmidt M, Hacein-Bey-Abina S, Wissler M, et al. Clonal evidence for the transduction of CD34(+) cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood. 2005;105:2699-2706.
6. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401-409.
7. Hacein-Bey-Abina S, Von KC, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415-419.
8. Hacein-Bey-Abina S, Von KC, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255-256.
9. Seggewiss R, Pittaluga S, Adler RL, et al. Acute myeloid leukemia associated with retroviral gene transfer to hematopoietic progenitor cells of a rhesus macaque. Blood. 2006;107:3865-3867.
10. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006;13:1031-1049.
11. Hoeben RC, Migchielsen AA, van der Jagt RC, van OH, van der Eb AJ. Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J Virol. 1991;65:904-912.
12. Challita PM, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci U S A. 1994;91:2567-2571.
13. Razin A. CpG methylation, chromatin structure and gene silencing: a three-way connection. EMBO J. 1998;17:4905-4908.
14. Klug CA, Cheshier S, Weissman IL. Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood. 2000;96:894-901.
15. Lorincz MC, Schubeler D, Hutchinson SR, Dickerson DR, Groudine M. DNA methylation density influences the stability of an epigenetic imprint and Dnmt3a/b-independent de novo methylation. Mol Cell Biol. 2002;22:7572-7580.
16. Yao S, Osborne CS, Bharadwaj RR, et al. Retrovirus silencer blocking by the cHS4 insulator is CTCF independent. Nucleic Acids Res. 2003;31:5317-5323.
17. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther. 2005;16:1241-1246.
18. Sinn PL, Sauter SL, McCray PB. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Ther. 2005;12:1089-1098.
19. Doerfler W, Remus R, Muller K, et al. The fate of foreign DNA in mammalian cells and organisms. Dev Biol (Basel). 2001;106:89-97.
20. Rosenqvist N, Hard Af Segerstad C, Samuelsson C, Johansen J, Lundberg C. Activation of silenced transgene expression in neural precursor cell lines by inhibitors of histone deacetylation. J Gene Med. 2002;4:248-257.
21. Williams S, Mustoe T, Mulcahy T, et al. CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/ enhancer in mammalian cells. BMC Biotechnol. 2005;5:17.
22. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72:9873-9880.
23. Modlich U, Kustikova OS, Schmidt M, et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood, 2005;105:4235-4246.
24. Modlich U, Bohne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood. 2006;108:2545-2553.
25. Kraunus J, Schaumann DH, Meyer J, et al. Self-inactivating retroviral vectors with improved RNA processing. Gene Ther. 2004;11:1568-1578.
26. Mitchell RS, Beitzel BF, Schroder AR, et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2004;2:E234.
27. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300:1749-1751.
28. Trono D. Virology: picking the right spot. Science. 2003;300:1670-1671.
29. Antoniou M, Harland L, Mustoe T, et al. Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics. 2003;82:269-279.
30. Pikaart MJ, Recillas-Targa F, Felsenfeld G. Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev. 1998;12:2852-2862.
31. Demaison C, Parsley K, Brouns G, et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther. 2002;13:803-813.
32. Chung YJ, Park BB, Kang YJ, et al. Unique effects of Stat3 on the early phase of hematopoietic stem cell regeneration. Blood. 2006;108:1208-1215.
33. Otsu M, Anderson SM, Bodine DM, et al. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol Ther. 2000;1:145-153.
34. Charrier S, Stockholm D, Seye K, et al. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther. 2005;12:597-606.
35. Ishii N, Asao H, Kimura Y, et al. Impairment of ligand binding and growth signaling of mutant IL-2 receptor gamma-chains in patients with Xlinked severe combined immunodeficiency. J Immunol. 1994;153:1310-1317.
36. Li Q, Peterson KR, Fang X, Stamatoyannopoulos G. Locus control regions. Blood. 2002;100:3077-3086.
37. Wang L, Robbins PB, Carbonaro DA, Kohn DB. High-resolution analysis of cytosine methylation in the 5long terminal repeat of retroviral vectors. Hum Gene Ther. 1998;9:2321-2330.
38. Bottardi S, Aumont A, Grosveld F, Milot E. Developmental stage-specific epigenetic control of human beta-globin gene expression is potentiated in hematopoietic progenitor cells prior to their transcriptional activation. Blood. 2003;102:3989-3997.
39. Dean A. On a chromosome far, far away: LCRs and gene expression. Trends Genet. 2006;22:38-45.
40. Persons DA, Tisdale JF. Gene therapy for the hemoglobin disorders. Semin Hematol. 2004;41:279-286.
41. Sadelain M. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Curr Opin Hematol. 2006;13:142-148.
42. Indraccolo S, Minuzzo S, Roccaforte F, et al. Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood. 2001;98:3607-3617.
43. Greaves DR, Wilson FD, Lang G, Kioussis D. Human CD2 3-flanking sequences confer highlevel, T cell-specific, position-independent gene expression in transgenic mice. Cell. 1989;56:979-986.
44. Collis P, Antoniou M, Grosveld F. Definition of the minimal requirements within the human beta-globin gene and the dominant control region for high level expression. EMBO J. 1990;9:233-240.
45. Antoniou M, Grosveld F. beta-globin dominant control region interacts differently with distal and proximal promoter elements. Genes Dev. 1990;4:1007-1013.
46. Chang AH, Stephan MT, Sadelain M. Stem cell-derived erythroid cells mediate long-term systemic protein delivery. Nat Biotechnol. 2006;24:1017-1021.
47. West AG, Gaszner M, Felsenfeld G. Insulators: many functions, many mechanisms. Genes Dev. 2002;16:271-288.
48. Gaszner M, Felsenfeld G. Insulators: exploiting transcriptional and epigenetic mechanisms. Nat Rev Genet. 2006;7:703-713.
49. Jakobsson J, Rosenqvist N, Thompson L, Barraud P, Lundberg C. Dynamics of transgene expression in a neural stem cell line transduced with lentiviral vectors incorporating the cHS4 insulator. Exp Cell Res. 2004;298:611-623.
50. Puthenveetil G, Scholes J, Carbonell D, et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood. 2004;104:3445-3453.